# Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Source: https://onco.cc/trials/nct06793553/  
OnCo record `nct06793553` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Japan Breast Cancer Research Group, now recruiting.

## Summary

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC is a phase 2, randomised interventional study registered as NCT06793553 by Japan Breast Cancer Research Group, with a registry enrolment figure of 106 participants, started 2024-09-13 and due to reach its primary completion in 2026-03-31. Interventions recorded: Induction therapy. Conditions listed: Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "Diagnosed with metastatic recurrent or unresectable advanced TNBC". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: INDUCE
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06793553
- Phase: 2
- Setting: Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at atEzolizumab+Nab-paclitaxel for PD-L1-positive Metastatic Triple Negative Breast Cancer (JBCRG-M10, CMA-0196) (INDUCE Trial)
- Sponsor: Japan Breast Cancer Research Group
- Enrolled: 106

## Sources

- ClinicalTrials.gov NCT06793553: https://clinicaltrials.gov/study/NCT06793553

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06793553.json